With growing calls to improve value in health care, the assessment of surgical outcomes has moved to the spotlight. Public awareness of medical errors has spurred initiatives like the ProPublica "Surgeon Scorecard" to measure and report complications (https://projects.propublica.org/surgeons/). High-tech and expensive innovations such as robot-assisted surgery must be measured against traditional approaches. Together, these factors and others have spurred calls to measure, assess and compare surgical techniques. The past months have seen publication of two high-profile randomized trials evaluating surgical techniques in urology. The first was early results from the first phase-3 randomized trial comparing open and robotic prostatectomy. [1] Second was the publication of 10-year outcomes from the ProtecT trial, comparing surgery, radiation and active monitoring for prostate cancer. [2] Using trials to evaluate techniques is seemingly obvious. Since James Lind's first Randomized controlled trials provide ironclad evidence on the superiority of drug A versus B or versus placebo. They can also provide key insight on some questions in surgery. However, at the same time, it is essential to understand how surgery is different. It is often said that surgery is more "an art than a science." While this cliché does not excuse us from applying scientific rigor, it does highlight that surgery may require novel evaluative approaches compared to prospective trials. We believe that novel; data-driven approaches that encompass the complexity of surgical care will provide key complementary insights for surgical evaluation and quality improvement in years to come.
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